AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10028374 — intervention group
Group type: EXPERIMENTAL
Intervention: New slow release tablet formulation (Pindac) 12.5 mg every 12 h for 7 days
Number of subjects: 18
Study 10028374 — intervention group
Group type: COMPARATOR
Intervention: Standard slow release capsule formulation 12.5 mg every 12 h for 7 days
Number of subjects: 18
Study 7672764 — intervention group
Group type: COMPARATOR
Intervention: Liver resection (Group A)
Number of subjects: 40
Study 7672764 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver resection combined with post-operative locoregional immunotherapy + chemotherapy (Group B)
Number of subjects: 40
Study 2285086 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary repair
Number of subjects: 150
Study 2285086 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-patellar tendon-bone augmentation
Number of subjects: 150
Study 2285086 — intervention group
Group type: EXPERIMENTAL
Intervention: Kennedy Ligament Augmentation Device
Number of subjects: 150
Study 7178370 — intervention group
Group type: EXPERIMENTAL
Intervention: Desimipramine (DMI)
Number of subjects: 6
Study 7178370 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg i.v.)
Number of subjects: 6
Study 7178370 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaclazepam (10 mg p.o. and 30 mg p.o.)
Number of subjects: 6
Study 7178370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30143879 — intervention group
Group type: EXPERIMENTAL
Intervention: Very thin-strut biodegradable polymer drug-eluting stents (BP-DES)
Number of subjects: 1009
Study 30143879 — intervention group
Group type: COMPARATOR
Intervention: Thin-strut durable polymer drug-eluting stents (DP-DES)
Number of subjects: 1009
Study 26773296 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insufficiency (measured by days of hunger in the past week)
Number of subjects: 1238
Study 26773296 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insufficiency among women with low levels of instrumental support
Number of subjects: 1238
Study 26773296 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insufficiency (quantile regression analysis)
Number of subjects: 1238
Study 26773296 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-effects regression models and fixed-effects quantile regression models
Number of subjects: 1238
Study 25899926 — intervention group
Group type: EXPERIMENTAL
Intervention: 1g of acetaminophen twice daily for 12 weeks
Number of subjects: 94
Study 25899926 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily for 12 weeks
Number of subjects: 94
Study 23113934 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training (IT) 3 times a week for 7 weeks
Number of subjects: 15
Study 23113934 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training (IT)
Number of subjects: 15
Study 20004370 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure genistein (n=21)
Number of subjects: 38
Study 20004370 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=17)
Number of subjects: 38
Study 18439196 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (5-7 minutes, adapted from classic motivational interviewing techniques)
Number of subjects: 292
Study 18439196 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 292
Study 18439196 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Number of subjects: 292
Study 18439196 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 292
Study 16682403 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (0.5 mg buserelin)
Number of subjects: 69
Study 16682403 — intervention group
Group type: COMPARATOR
Intervention: hCG (10,000 IU)
Number of subjects: 69
Study 12791434 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg memantine/day
Number of subjects: 36
Study 12791434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 10686270 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride (.5 mg/kg)
Number of subjects: 7
Study 10686270 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 7
Study 9315417 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal film containing 19 mg BZK
Number of subjects: 10
Study 9315417 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal film containing 25 mg BZK
Number of subjects: 10
Study 9315417 — intervention group
Group type: COMPARATOR
Intervention: VCF containing 70 mg N‐9
Number of subjects: 10
Study 9315417 — intervention group
Group type: COMPARATOR
Intervention: Baseline cycles (no film used)
Number of subjects: 10
Study 9315417 — intervention group
Group type: EXPERIMENTAL
Intervention: Colposcopy with BZK films
Number of subjects: 10
Study 9315417 — intervention group
Group type: COMPARATOR
Intervention: Colposcopy with VCF
Number of subjects: 10
Study 9315417 — intervention group
Group type: COMPARATOR
Intervention: Colposcopy in baseline cycles
Number of subjects: 10
Study 9315417 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptability of films
Number of subjects: 10
Study 1586375 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation A (40 mg slow-release isosorbide mononitrate)
Number of subjects: 18
Study 1586375 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation B (40 mg slow-release isosorbide mononitrate)
Number of subjects: 18
Study 1586375 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation C (40 mg slow-release isosorbide mononitrate)
Number of subjects: 18
Study 1586375 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure and heart rate (pharmacodynamic effects)
Number of subjects: 18
Study 3991283 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% reimbursement for health costs
Number of subjects: 1136
Study 3991283 — intervention group
Group type: COMPARATOR
Intervention: 95% cost-sharing
Number of subjects: 1136
Study 3991283 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive care treatment episodes
Number of subjects: 1136
Study 3991283 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital expenditures
Number of subjects: 1136
Study 28952800 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed message
Number of subjects: 156
Study 28952800 — intervention group
Group type: EXPERIMENTAL
Intervention: Any anti-binge drinking messages (loss-framed or gain-framed)
Number of subjects: 156
Study 28952800 — intervention group
Group type: COMPARATOR
Intervention: Control group (no messages)
Number of subjects: 156
Study 26354383 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meal (550 kcal)
Number of subjects: 36
Study 26354383 — intervention group
Group type: COMPARATOR
Intervention: Glucose challenge alone
Number of subjects: 36
Study 25066449 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 30
Study 25066449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 24343979 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation and problem solving (PEPS) trial
Number of subjects: 90
Study 20543706 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy initiated a median of 7 weeks before delivery (cohort A)
Number of subjects: 248
Study 20543706 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine from 34 to 36 weeks gestation until delivery with single-dose nevirapine in labor (cohort B)
Number of subjects: 248
Study 18950302 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial overdrive pacing
Number of subjects: 451
Study 18950302 — intervention group
Group type: COMPARATOR
Intervention: DDDR pacing
Number of subjects: 451
Study 18950302 — intervention group
Group type: COMPARATOR
Intervention: Closed loop (CLS) pacing
Number of subjects: 451
Study 15957509 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir (3000 mg/day)
Number of subjects: 58
Study 15957509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 12527967 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise
Number of subjects: 0
Study 12527967 — intervention group
Group type: COMPARATOR
Intervention: Field running
Number of subjects: 0
Study 10407231 — intervention group
Group type: EXPERIMENTAL
Intervention: Summary statistics
Number of subjects: 240
Study 10407231 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated measures analysis of variance (RMAOV)
Number of subjects: 240
Study 10407231 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginal models (generalized estimating equation methodology)
Number of subjects: 240
Study 10407231 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel models (hierarchical random effects models)
Number of subjects: 240
Study 8890680 — intervention group
Group type: EXPERIMENTAL
Intervention: d-fenfluramine
Number of subjects: 28
Study 8890680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 2062621 — intervention group
Group type: EXPERIMENTAL
Intervention: HbOC vaccine (three doses at 2, 4, and 6 months of age)
Number of subjects: 20800
Study 2062621 — intervention group
Group type: EXPERIMENTAL
Intervention: HbOC vaccine (two doses)
Number of subjects: 20800
Study 2062621 — intervention group
Group type: EXPERIMENTAL
Intervention: HbOC vaccine (one dose)
Number of subjects: 20800
Study 6203496 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 21
Study 6203496 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive treatments (ECTs)
Number of subjects: 21
Study 6203496 — intervention group
Group type: COMPARATOR
Intervention: Different antidepressant treatments
Number of subjects: 21
Study 30328701 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted education
Number of subjects: 67
Study 30328701 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 67
Study 30051571 — intervention group
Group type: EXPERIMENTAL
Intervention: Eliava Pyophage (monospecies counterpart)
Number of subjects: 0
Study 30051571 — intervention group
Group type: EXPERIMENTAL
Intervention: Phage cocktail
Number of subjects: 0
Study 30051571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27319097 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural Droperidol
Number of subjects: 86
Study 27319097 — intervention group
Group type: COMPARATOR
Intervention: Epidural Adrenaline
Number of subjects: 86
Study 25282871 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week self-administered weight lifting program
Number of subjects: 23
Study 22780937 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimotuzumab (200 mg per week for 6 weeks), palitaxel liposome 160 mg/m2, and carboplatin (AUC = 6)
Number of subjects: 41
Study 22780937 — intervention group
Group type: COMPARATOR
Intervention: LP regimen (palitaxel liposome and carboplatin)
Number of subjects: 41
Study 22780937 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimotuzumab plus LP regimen
Number of subjects: 41
Study 22780937 — intervention group
Group type: COMPARATOR
Intervention: LP regimen
Number of subjects: 41
Study 22780937 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study 20547990 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg daily)
Number of subjects: 0
Study 20547990 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (20 mg daily)
Number of subjects: 0
Study 20547990 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 0
Study 20547990 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole vs Tamoxifen
Number of subjects: 0
Study 15984909 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine 20mg three times daily
Number of subjects: 200
Study 15984909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 12860863 — intervention group
Group type: EXPERIMENTAL
Intervention: NT pro BNP above median concentration
Number of subjects: 87
Study 12860863 — intervention group
Group type: COMPARATOR
Intervention: NT pro BNP below median concentration
Number of subjects: 87
Study 12860863 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxin above median concentration
Number of subjects: 87
Study 12860863 — intervention group
Group type: COMPARATOR
Intervention: Relaxin below median concentration
Number of subjects: 87
Study 11776548 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen-conserving nasal cannula (CNC)
Number of subjects: 0
Study 11776548 — intervention group
Group type: COMPARATOR
Intervention: Oxygen-conserving nasal cannula (CNC) at 0.5 L/min
Number of subjects: 0
Study 11776548 — intervention group
Group type: COMPARATOR
Intervention: Oxygen-conserving nasal cannula (CNC) at 1.0 L/min
Number of subjects: 0
Study 11776548 — intervention group
Group type: COMPARATOR
Intervention: Oxygen-conserving nasal cannula (CNC) at 1.5 L/min
Number of subjects: 0
Study 11776548 — intervention group
Group type: COMPARATOR
Intervention: Oxygen-conserving nasal cannula (CNC) at 2.0 L/min
Number of subjects: 0
Study 8526700 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment intervention started before hospital discharge and continued at home
Number of subjects: 354
Study 8526700 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 354
Study 8526700 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment intervention
Number of subjects: 354
Study 10149803 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution B-mode ultrasound imaging
Number of subjects: 16000
Study 6839666 — intervention group
Group type: EXPERIMENTAL
Intervention: Static handgrip
Number of subjects: 6
Study 6839666 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic handgrip
Number of subjects: 6
Study 6839666 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (without drugs)
Number of subjects: 6
Study 6839666 — intervention group
Group type: COMPARATOR
Intervention: Autonomic blockade (atropine and metoprolol)
Number of subjects: 6
Study 29254367 — intervention group
Group type: EXPERIMENTAL
Intervention: Group intervention program (four weekly sessions)
Number of subjects: 60
Study 29254367 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 60
Study 28721992 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-pocket 20% benzocaine gel
Number of subjects: 15
Study 28721992 — intervention group
Group type: COMPARATOR
Intervention: Infiltration/block by 2% lidocaine with 1:80,000 adrenaline
Number of subjects: 15
Study 26700836 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI) alone (n = 78)
Number of subjects: 205
Study 26700836 — intervention group
Group type: COMPARATOR
Intervention: Full defragmentation (full defrag) approach (n = 75)
Number of subjects: 205
Study 23915222 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency manipulation in the computerized task
Number of subjects: 0
Study 23915222 — intervention group
Group type: COMPARATOR
Intervention: Similarity manipulation in the computerized task
Number of subjects: 0
Study 21423021 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-informed dosing algorithms
Number of subjects: 230
Study 21423021 — intervention group
Group type: COMPARATOR
Intervention: Clinical dosing algorithms
Number of subjects: 230
Study 18503551 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied 5% vitamin C and 0.1% madecassoside
Number of subjects: 20
Study 16341856 — intervention group
Group type: EXPERIMENTAL
Intervention: LI 160 (HYF 41 mg/day)
Number of subjects: 42
Study 16341856 — intervention group
Group type: EXPERIMENTAL
Intervention: SJW powder tablets 2.7 g/day (HYF 12 mg/day)
Number of subjects: 42
Study 16341856 — intervention group
Group type: EXPERIMENTAL
Intervention: SJW powder tablets 2.7 g/day (HYF 0.13 mg/day)
Number of subjects: 42
Study 12894080 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nitrogen mustard
Number of subjects: 6
Study 12894080 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 6
Study 11145006 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 93
Study 8854742 — intervention group
Group type: EXPERIMENTAL
Intervention: Attended tone pips
Number of subjects: 0
Study 8854742 — intervention group
Group type: COMPARATOR
Intervention: Nonattended tone pips
Number of subjects: 0
Study 8854742 — intervention group
Group type: EXPERIMENTAL
Intervention: All tone pips
Number of subjects: 0
Study 1371341 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (Infant Health and Development Program)
Number of subjects: 985
Study 1371341 — intervention group
Group type: COMPARATOR
Intervention: Control (pediatric follow-up and referral services only)
Number of subjects: 985
Study 6661512 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol hydrochloride (2 X 40 mg)
Number of subjects: 10
Study 29458343 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART adherence
Number of subjects: 792
Study 27455419 — intervention group
Group type: EXPERIMENTAL
Intervention: Water exercises rehabilitation program
Number of subjects: 192
Study 27455419 — intervention group
Group type: COMPARATOR
Intervention: Kinesitherapy and low-frequency magnetic field rehabilitation program
Number of subjects: 192
Study 24100464 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training (24 sessions over 8 weeks, 3 sessions per week)
Number of subjects: 36
Study 22105879 — intervention group
Group type: EXPERIMENTAL
Intervention: MGuard net protective stent (MGS) implantation
Number of subjects: 556
Study 22105879 — intervention group
Group type: COMPARATOR
Intervention: Manual thrombectomy (MT) pretreatment followed by bare-metal stent (BMS) implantation
Number of subjects: 556
Study 20832848 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic formula group (formula containing a specific mixture of neutral oligosaccharides and pectin-derived acidic oligosaccharides)
Number of subjects: 414
Study 20832848 — intervention group
Group type: COMPARATOR
Intervention: Control formula group (regular formula without oligosaccharides)
Number of subjects: 414
Study 20832848 — intervention group
Group type: COMPARATOR
Intervention: Breast-feeding group
Number of subjects: 414
Study 20832848 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic formula group
Number of subjects: 414
Study 18664348 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp-acupuncture
Number of subjects: 92
Study 18664348 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 92
Study 17038251 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 42
Study 17038251 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition
Number of subjects: 42
Study 17038251 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 12355570 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine preparations with laser assistance
Number of subjects: 80
Study 12355570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 10336914 — intervention group
Group type: EXPERIMENTAL
Intervention: VDD pacemaker
Number of subjects: 441
Study 10336914 — intervention group
Group type: COMPARATOR
Intervention: DDD pacemaker
Number of subjects: 441
Study 10336914 — intervention group
Group type: COMPARATOR
Intervention: Both VDD and DDD pacemakers
Number of subjects: 441
Study 7528712 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506 (Tacrolimus) treatment without cellular rejection
Number of subjects: 17
Study 7528712 — intervention group
Group type: COMPARATOR
Intervention: FK506 (Tacrolimus) treatment with cellular rejection
Number of subjects: 17
Study 2168586 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1200 mg daily)
Number of subjects: 31
Study 2168586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 6159865 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine hydrochloride treatment for 3 weeks
Number of subjects: 0
Study 31449156 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic patients after a protein meal
Number of subjects: 301
Study 31449156 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (HVs)
Number of subjects: 301
Study 30729346 — intervention group
Group type: EXPERIMENTAL
Intervention: Supragingival debridement (SD) with adjunctive full mouth glycine powder air polishing (FM‐GPAP) (test, n = 42)
Number of subjects: 87
Study 30729346 — intervention group
Group type: COMPARATOR
Intervention: Supragingival debridement (SD) alone (control, n = 45)
Number of subjects: 87
Study 30729346 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (test and control)
Number of subjects: 87
Study 28938500 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy
Number of subjects: 1497
Study 28938500 — intervention group
Group type: COMPARATOR
Intervention: Fecal immunochemical testing (FIT)
Number of subjects: 1497
Study 25981758 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor (600 mg once daily or 400 mg every 12 hours) in combination with ivacaftor (250 mg every 12 hours)
Number of subjects: 1108
Study 25981758 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor-ivacaftor groups
Number of subjects: 1108
Study 25981758 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor-ivacaftor
Number of subjects: 1108
Study 25981758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1108
Study 24268876 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 0
Study 24268876 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 0
Study 24268876 — intervention group
Group type: COMPARATOR
Intervention: Pessary treatment
Number of subjects: 0
Study 21633072 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain velocity between 12 and 34 months
Number of subjects: 10494
Study 19375250 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate treatment (1500 mg/day by Day 6)
Number of subjects: 20
Study 19375250 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate treatment
Number of subjects: 20
Study 19375250 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20